This article is more than 5 years old. Information may no longer be current.

OSN’s top news of the week

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Here are the top stories for Healio.com/Ophthalmology in the past week:

Eyenovia ’ s piezo-print latanoprost microdose shows positive results

The EYN PG21 study evaluated 60 eyes of 30 healthy volunteers who received one microdose of piezo-print latanoprost each day for 2 consecutive days. Read more.

FDA approves Sun Pharma’s dry eye treatment

Cequa (cyclosporine ophthalmic solution 0.09%), the highest FDA-approved concentration of cyclosporine A and the first to incorporate nanomicellar technology, is indicated to increase tear production. Read more.

FDA approves Hydrus microstent

Ivantis announced the FDA approval of the Hydrus microstent, designed to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. Read more.

At Issue: Ensuring LASIK success and minimizing complications

Healio.com/OSN spoke with three refractive surgery experts — John Berdahl, MD, George O. Waring IV, MD, and Richard Duffey, MD — who shared their opinions on laser vision correction surgery. Read more.

FDA approves Eylea 12-week dosing for wet AMD

The FDA has approved a supplemental biologics license application for a 12-week dosing schedule of Eylea injection in wet age-related macular degeneration patients. Read more.